secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001437749-23-029660
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q3 total net revenue $165.8M; BRIUMVI net sales $25.1M, net income $113.9M
--------------------------------------------------------------------------------

- BRIUMVI net sales $25.1M in Q3; ~$48.9M cumulative since launch; ~2,200 prescriptions from 500+ providers.
- License revenue $140.0M from Neuraxpharm upfront for ex-U.S. commercialization of BRIUMVI in RMS.
- Net income $113.9M vs net loss $35.8M YoY; cash position $229.2M as of Sept 30, 2023.
- Payor coverage for ~95% of covered lives; permanent J-Code (J2329) effective July 1, 2023.
- Company expects existing cash plus BRIUMVI revenues to fund operations into cash flow positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/0001437749-23-029660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/tgtx20231030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-029660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer